These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31183899)

  • 21. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
    J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Pragmatic Approach to Prostate Cancer Screening.
    Tosoian JJ; Penson DF; Chinnaiyan AM
    JAMA; 2024 May; 331(17):1448-1450. PubMed ID: 38581253
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.
    Kato T; Hirama H; Kamoto T; Goto T; Fujimoto H; Sakamoto S; Shinohara N; Egawa S; Kouguchi D; Nakayama M; Hashine K; Shimizu N; Inoue K; Habuchi T; Hioka T; Shiraishi T; Sugimoto M; Kakehi Y
    Int J Clin Oncol; 2024 Oct; 29(10):1557-1563. PubMed ID: 39085727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols.
    Kang HW; Lee JY; Kwon JK; Jeh SU; Jung HD; Cho KS; Ham WS; Choi YD
    J Korean Med Sci; 2015 Jul; 30(7):932-6. PubMed ID: 26130957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL.
    Fujizuka Y; Ito K; Oki R; Suzuki R; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
    Int J Urol; 2017 Aug; 24(8):602-609. PubMed ID: 28560739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
    Huland H; Graefen M
    Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-specific reference range of prostate-specific antigen and prostate cancer detection in population-based screening cohort in Japan: verification of Japanese Urological Association Guideline for prostate cancer.
    Kitagawa Y; Izumi K; Sawada K; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
    Int J Urol; 2014 Nov; 21(11):1120-5. PubMed ID: 24931145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
    Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
    J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
    Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
    J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Discontinuation of Active Surveillance among Men with Low-Risk Prostate Cancer: A Population-Based Study.
    Timilshina N; Komisarenko M; Martin LJ; Cheung DC; Alibhai S; Richard PO; Finelli A
    J Urol; 2021 Oct; 206(4):903-913. PubMed ID: 34412510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
    Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
    J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
    Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-year nationwide follow-up study of active surveillance for prostate cancer.
    Loeb S; Folkvaljon Y; Makarov DV; Bratt O; Bill-Axelson A; Stattin P
    Eur Urol; 2015 Feb; 67(2):233-8. PubMed ID: 24993868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
    Van Hemelrijck M; Ji X; Helleman J; Roobol MJ; van der Linden W; Nieboer D; Bangma CH; Frydenberg M; Rannikko A; Lee LS; Gnanapragasam VJ; Kattan MW; ;
    Eur Urol; 2019 Mar; 75(3):523-531. PubMed ID: 30385049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strengthening evidence for active surveillance for prostate cancer.
    Klotz L
    Eur Urol; 2013 Jan; 63(1):108-10. PubMed ID: 23122665
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort.
    Marzouk K; Assel M; Ehdaie B; Vickers A
    J Urol; 2018 Dec; 200(6):1250-1255. PubMed ID: 29886089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.